311 related articles for article (PubMed ID: 33144118)
1. Targeting post-translational histone modifying enzymes in glioblastoma.
Kunadis E; Lakiotaki E; Korkolopoulou P; Piperi C
Pharmacol Ther; 2021 Apr; 220():107721. PubMed ID: 33144118
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
3. Role of histone lysine methyltransferases SUV39H1 and SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and colony formation.
Spyropoulou A; Gargalionis A; Dalagiorgou G; Adamopoulos C; Papavassiliou KA; Lea RW; Piperi C; Papavassiliou AG
Neuromolecular Med; 2014 Mar; 16(1):70-82. PubMed ID: 23943221
[TBL] [Abstract][Full Text] [Related]
4. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
5. The application of histone deacetylases inhibitors in glioblastoma.
Chen R; Zhang M; Zhou Y; Guo W; Yi M; Zhang Z; Ding Y; Wang Y
J Exp Clin Cancer Res; 2020 Jul; 39(1):138. PubMed ID: 32682428
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
7. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
8. Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.
Pacaud R; Cheray M; Nadaradjane A; Vallette FM; Cartron PF
Theranostics; 2015; 5(1):12-22. PubMed ID: 25553095
[TBL] [Abstract][Full Text] [Related]
9. The function of histone methylation and acetylation regulators in GBM pathophysiology.
McCornack C; Woodiwiss T; Hardi A; Yano H; Kim AH
Front Oncol; 2023; 13():1144184. PubMed ID: 37205197
[TBL] [Abstract][Full Text] [Related]
10. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
11. Specific combinations of the chromatin-modifying enzyme modulators significantly attenuate glioblastoma cell proliferation and viability while exerting minimal effect on normal adult stem cells growth.
Alexanian AR; Huang YW
Tumour Biol; 2015 Nov; 36(11):9067-72. PubMed ID: 26084611
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Mechanisms Histone Deacetylase-Dependent Regulate the Glioblastoma Angiogenic Matrisome and Disrupt Endothelial Cell Behavior In Vitro.
Menezes A; Julião G; Mariath F; Ferreira AL; Oliveira-Nunes MC; Gallucci L; Evaristo JAM; Nogueira FCS; Pereira DA; Carneiro K
Mol Cell Proteomics; 2024 Mar; 23(3):100722. PubMed ID: 38272115
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches.
Uddin MS; Mamun AA; Alghamdi BS; Tewari D; Jeandet P; Sarwar MS; Ashraf GM
Semin Cancer Biol; 2022 Aug; 83():100-120. PubMed ID: 33370605
[TBL] [Abstract][Full Text] [Related]
14. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
[TBL] [Abstract][Full Text] [Related]
15. Role of Lysine-specific Demethylase 1 and Its Small Molecule Inhibitors in Glioblastoma Multiforme Therapy.
Mitra R; Ayyannan SR
Anticancer Agents Med Chem; 2022; 22(18):3062-3085. PubMed ID: 35593350
[TBL] [Abstract][Full Text] [Related]
16. Deregulated chromatin remodeling in the pathobiology of brain tumors.
Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Underpinnings of Inflammation: A Key to Unlock the Tumor Microenvironment in Glioblastoma.
Chen N; Peng C; Li D
Front Immunol; 2022; 13():869307. PubMed ID: 35572545
[TBL] [Abstract][Full Text] [Related]
18. An update on the epigenetics of glioblastomas.
Ferreira WA; Pinheiro Ddo R; Costa Junior CA; Rodrigues-Antunes S; Araújo MD; Leão Barros MB; Teixeira AC; Faro TA; Burbano RR; Oliveira EH; Harada ML; Borges Bdo N
Epigenomics; 2016 Sep; 8(9):1289-305. PubMed ID: 27585647
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
Lu VM; Daniels DJ
Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
[TBL] [Abstract][Full Text] [Related]
20. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy.
Zheng YG; Wu J; Chen Z; Goodman M
Med Res Rev; 2008 Sep; 28(5):645-87. PubMed ID: 18271058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
